Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | GFER | P55789 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | IKBKB | O14920 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 4/20 | 0.53 |
| ▸ | HNF4A | P41235 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27768999 | 0.86 | PPM1B (0.63) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL2246915 | 0.85 | KMT2A (0.84) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL352643 | 0.85 | KMT2A (1.00) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL1954450 | 0.85 | KMT2A (1.00) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL29498389 | 0.85 | KMT2A (1.00) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL28147599 | 0.84 | HSD17B1 (0.59) | MCL1HSD17B1HSD17B2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL8024368 | 0.83 | KMT2A (0.95) | KMT2AKDM4EGFERRXFP1IKBKB | |
| SCHEMBL3865083 | 0.83 | KMT2A (0.95) | KMT2AKDM4EGFERRXFP1IKBKB | |
| Methane SCHEMBL29001097 | 0.83 | KMT2A (0.95) | KMT2AKDM4EGFERRXFP1IKBKB | |
| Ammonia Solution, Strong SCHEMBL5271744 | 0.83 | KMT2A (0.95) | KMT2AKDM4EGFERRXFP1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1351979-B1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | CASR, TRPM8, TRPM6 | KMT2A 3357/4885KDM4E 4471/4885GFER 1567/4885 |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KMT2A 1838/4885KDM4E 3202/4885GFER 3587/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KMT2A 1838/4885KDM4E 3202/4885GFER 3587/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KMT2A 1838/4885KDM4E 3202/4885GFER 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.